Suppr超能文献

188例耐多药肺结核的外科治疗

[Surgical treatment of multi-drug resistant pulmonary tuberculosis in 188 cases].

作者信息

Li Wen-tao, Jiang Ge-ning, Gao Wen, Xiao He-ping, Ding Jia-an

机构信息

Department of Thoracic Surgery, Shanghai Pulmonary Disease Hospital, Shanghai 200433, China.

出版信息

Zhonghua Jie He He Hu Xi Za Zhi. 2006 Aug;29(8):524-6.

Abstract

OBJECTIVE

Multi-drug resistant pulmonary tuberculosis (MDR-PTB) is a major cause of morbidity and mortality throughout the world currently. Optimal therapy for patients infected with MDR-PTB often requires surgical intervention to eradicate the infection.

METHODS

During a 15-year period from 1990 to 2005, of the 906 cases receiving surgical treatment for pulmonary tuberculosis in Shanghai Pulmonary Disease Hospital, 188 patients with MDR-PTB underwent 200 surgical procedures. All the patients of MDR-PTB had received individualized multiple-drug chemotherapy at least 2 - 3 months before surgery, as determined by drug susceptibility studies. Of the surgical procedures, 85 lobectomies, 48 pneumonectomies and other complicated surgical techniques were performed respectively. Twelve patients underwent repeated operation. Muscle flaps and omentum in some cases were used to avoid residual space and bronchial stump problems.

RESULTS

Operative mortality was 0.5% (1/200). Postoperative mortality was 3.2% (6/187). Significant morbidity was 13.9% (26/187). All of the patients had positive sputum at the time of surgery. After the operation, the sputum remained positive in only 2 patients. Mean length of follow-up was 6.7 years (range 3 - 180 months). All of the patients after surgery continued their individualized multiple-drug chemotherapy for 3 - 18 months.

CONCLUSION

Surgery remains an important adjunct to medical therapy for the treatment of MDR-PTB. Surgical treatment should be considered for localized diseases, persistent sputum positivity, or intolerance of medical therapy.

摘要

目的

耐多药肺结核(MDR-PTB)是当前全球发病和死亡的主要原因。对感染MDR-PTB的患者进行最佳治疗通常需要手术干预以根除感染。

方法

在1990年至2005年的15年期间,上海肺科医院906例接受肺结核手术治疗的患者中,188例MDR-PTB患者接受了200次手术。所有MDR-PTB患者在手术前至少2 - 3个月根据药敏试验结果接受了个体化的多药化疗。手术方式分别为85例肺叶切除术、48例全肺切除术及其他复杂手术技术。12例患者接受了再次手术。部分病例使用肌瓣和大网膜以避免残腔和支气管残端问题。

结果

手术死亡率为0.5%(1/200)。术后死亡率为3.2%(6/187)。严重并发症发生率为13.9%(26/187)。所有患者手术时痰菌均阳性。术后仅2例患者痰菌仍为阳性。平均随访时间为6.7年(范围3 - 180个月)。所有患者术后继续接受个体化的多药化疗3 - 18个月。

结论

手术仍然是治疗MDR-PTB药物治疗的重要辅助手段。对于局限性疾病、持续痰菌阳性或不耐受药物治疗的患者应考虑手术治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验